Literature DB >> 20203004

Detection of exon 12 Mutations in the JAK2 gene: enhanced analytical sensitivity using clamped PCR and nucleotide sequencing.

Todd S Laughlin1, Alison R Moliterno, Brady L Stein, Paul G Rothberg.   

Abstract

JAK2 V617F is the most frequently found somatic mutation in polycythemia vera (PV). Among the cases negative for V617F, a significant fraction have a mutation in exon 12 of the JAK2 gene. Several groups have reported that the exon 12 mutations are present in only a small fraction of the blood cells in some patients. We have developed an assay to detect these mutations with an analytical sensitivity of 0.1% by using a "PCR clamp" to inhibit amplification of the normal sequence and enhance amplification of DNA containing a mutation in the clamp target sequence. The products of this reaction were analyzed by capillary electrophoresis to detect deletions, which are the most frequent type of exon 12 mutations, or by nucleotide sequencing to detect all of the mutations. In a survey of 34 specimens from patients with PV or idiopathic erythrocytosis who did not have a JAK2 V617F mutation, we found four with a mutation in exon 12, 3 of 10 with PV, and 1 of 24 with idiopathic erythrocytosis. In two cases the mutation was present in a small fraction of the cells and difficult to detect without the use of the clamp. The use of an assay with increased analytical sensitivity enhances the ability to identify patients with mutations in exon 12 of the JAK2 gene.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20203004      PMCID: PMC2860462          DOI: 10.2353/jmoldx.2010.090177

Source DB:  PubMed          Journal:  J Mol Diagn        ISSN: 1525-1578            Impact factor:   5.568


  35 in total

1.  A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.

Authors:  Chloé James; Valérie Ugo; Jean-Pierre Le Couédic; Judith Staerk; François Delhommeau; Catherine Lacout; Loïc Garçon; Hana Raslova; Roland Berger; Annelise Bennaceur-Griscelli; Jean Luc Villeval; Stefan N Constantinescu; Nicole Casadevall; William Vainchenker
Journal:  Nature       Date:  2005-04-28       Impact factor: 49.962

2.  Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.

Authors:  Ross L Levine; Martha Wadleigh; Jan Cools; Benjamin L Ebert; Gerlinde Wernig; Brian J P Huntly; Titus J Boggon; Iwona Wlodarska; Jennifer J Clark; Sandra Moore; Jennifer Adelsperger; Sumin Koo; Jeffrey C Lee; Stacey Gabriel; Thomas Mercher; Alan D'Andrea; Stefan Fröhling; Konstanze Döhner; Peter Marynen; Peter Vandenberghe; Ruben A Mesa; Ayalew Tefferi; James D Griffin; Michael J Eck; William R Sellers; Matthew Meyerson; Todd R Golub; Stephanie J Lee; D Gary Gilliland
Journal:  Cancer Cell       Date:  2005-04       Impact factor: 31.743

3.  Single base pair mutation analysis by PNA directed PCR clamping.

Authors:  H Orum; P E Nielsen; M Egholm; R H Berg; O Buchardt; C Stanley
Journal:  Nucleic Acids Res       Date:  1993-11-25       Impact factor: 16.971

4.  Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.

Authors:  E Joanna Baxter; Linda M Scott; Peter J Campbell; Clare East; Nasios Fourouclas; Soheila Swanton; George S Vassiliou; Anthony J Bench; Elaine M Boyd; Natasha Curtin; Mike A Scott; Wendy N Erber; Anthony R Green
Journal:  Lancet       Date:  2005 Mar 19-25       Impact factor: 79.321

5.  Chromosome translocations and covert leukemic clones are generated during normal fetal development.

Authors:  Hiroshi Mori; Susan M Colman; Zhijian Xiao; Anthony M Ford; Lyn E Healy; Craig Donaldson; Jill M Hows; Cristina Navarrete; Mel Greaves
Journal:  Proc Natl Acad Sci U S A       Date:  2002-06-04       Impact factor: 11.205

6.  A gain-of-function mutation of JAK2 in myeloproliferative disorders.

Authors:  Robert Kralovics; Francesco Passamonti; Andreas S Buser; Soon-Siong Teo; Ralph Tiedt; Jakob R Passweg; Andre Tichelli; Mario Cazzola; Radek C Skoda
Journal:  N Engl J Med       Date:  2005-04-28       Impact factor: 91.245

Review 7.  The complete evaluation of erythrocytosis: congenital and acquired.

Authors:  M M Patnaik; A Tefferi
Journal:  Leukemia       Date:  2009-03-19       Impact factor: 11.528

8.  Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals.

Authors:  C Biernaux; M Loos; A Sels; G Huez; P Stryckmans
Journal:  Blood       Date:  1995-10-15       Impact factor: 22.113

9.  The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease.

Authors:  S Bose; M Deininger; J Gora-Tybor; J M Goldman; J V Melo
Journal:  Blood       Date:  1998-11-01       Impact factor: 22.113

10.  Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols.

Authors:  P D Berk; J D Goldberg; P B Donovan; S M Fruchtman; N I Berlin; L R Wasserman
Journal:  Semin Hematol       Date:  1986-04       Impact factor: 3.851

View more
  5 in total

1.  A highly sensitive quantitative real-time PCR assay for determination of mutant JAK2 exon 12 allele burden.

Authors:  Lasse Kjær; Maj Westman; Caroline Hasselbalch Riley; Estrid Høgdall; Ole Weis Bjerrum; Hans Hasselbalch
Journal:  PLoS One       Date:  2012-03-05       Impact factor: 3.240

2.  Detection of Exon 12 and 14 Mutations in Janus Kinase 2 Gene Including a Novel Mutant in V617F Negative Polycythemia Vera Patients from Pakistan.

Authors:  Afia Muhammad Akram; Humera Kausar; Asma Chaudhary; Ahmad Mukhtar Khalid; Muhammad Mudassar Shahzad; Muhammad Waheed Akhtar; Muhammad Farooq Sabar; Nadia Sajid; Nawaf Al Anazi; Aamer Aleem; Zafar Iqbal
Journal:  J Cancer       Date:  2018-10-21       Impact factor: 4.207

3.  Cytogenetics, JAK2 and MPL mutations in polycythemia vera, primary myelofibrosis and essential thrombocythemia.

Authors:  Leonardo Caires Dos Santos; Juliana Corrêa da Costa Ribeiro; Neusa Pereira Silva; Janete Cerutti; Maria Regina Regis da Silva; Maria de Lourdes Lopes Ferrari Chauffaille
Journal:  Rev Bras Hematol Hemoter       Date:  2011

4.  A Novel Homozygous Nucleotide Deletion in the JAK2 Gene in a Pediatric Patient with B-cell Precursor Acute Lymphoblastic Leukemia.

Authors:  Dilara Fatma Akın; Emel Akkaya; A Emin Kürekçi; Ciğdem Arslan; Ustün Ezer; Nejat Akar
Journal:  Turk J Haematol       Date:  2012-06-15       Impact factor: 1.831

5.  Myeloproliferative neoplasms and the JAK/STAT signaling pathway: an overview.

Authors:  Renata Mendes de Freitas; Carlos Magno da Costa Maranduba
Journal:  Rev Bras Hematol Hemoter       Date:  2015-06-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.